Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite therapy with surgery, radiation and chemotherapy, the prognosis remains poor, and the demand for more effective treatments is high. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression, including the epidermal growth factor receptor (EGFR) and downstream phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. Targeted therapeutics have been developed against these receptors and pathways. This article will review the rationale and current evidence for inhibitors of this signaling axis.
Keywords: Glioblastoma, EGFR inhibitors, mTOR inhibitors, treatments, review, chemotherapy, disease, Epidermal growth, phosphatidylinositol, mammalian target, rapamycin, high frequency, phenotype, tyrosine, chromosome, glycoprotein, cell, protein kinase C, tumor proliferation, exons, ligand binding, immunohistochemistry, antibodies, vaccines, glioma, oral, tissue, phosphorylation, hepatic enzyme system, cetuximab, solubility, blood concentration ratios, liver, hybridization, dose, enzyme, anti-epileptic, vaccine, mutations, tumor, temsirolimus, cholesterolemia, lymphopenia, tyrosine kinase receptor
Current Cancer Therapy Reviews
Title: Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Volume: 7 Issue: 1
Author(s): Eudocia C. Quant, Catherine L. Nutt, Daphne Wang and Tracy T. Batchelor
Affiliation:
Keywords: Glioblastoma, EGFR inhibitors, mTOR inhibitors, treatments, review, chemotherapy, disease, Epidermal growth, phosphatidylinositol, mammalian target, rapamycin, high frequency, phenotype, tyrosine, chromosome, glycoprotein, cell, protein kinase C, tumor proliferation, exons, ligand binding, immunohistochemistry, antibodies, vaccines, glioma, oral, tissue, phosphorylation, hepatic enzyme system, cetuximab, solubility, blood concentration ratios, liver, hybridization, dose, enzyme, anti-epileptic, vaccine, mutations, tumor, temsirolimus, cholesterolemia, lymphopenia, tyrosine kinase receptor
Abstract: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite therapy with surgery, radiation and chemotherapy, the prognosis remains poor, and the demand for more effective treatments is high. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression, including the epidermal growth factor receptor (EGFR) and downstream phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. Targeted therapeutics have been developed against these receptors and pathways. This article will review the rationale and current evidence for inhibitors of this signaling axis.
Export Options
About this article
Cite this article as:
C. Quant Eudocia, L. Nutt Catherine, Wang Daphne and T. Batchelor Tracy, Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma, Current Cancer Therapy Reviews 2011; 7 (1) . https://dx.doi.org/10.2174/157339411794474146
DOI https://dx.doi.org/10.2174/157339411794474146 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging Drug Resistance with Radiolabeled Molecules
Current Pharmaceutical Design Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Anti-Cancer Agents in Medicinal Chemistry Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design The Potential Therapeutic Value of Renin-Angiotensin System Inhibitors in the Treatment of Colorectal Cancer
Current Pharmaceutical Design Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry Design and Development of Glutathione Conjugated Poly (d, l) lactide Nanocarriers for Delivery of Hydrophilic Fluorescent Marker across Blood Brain Barrier
Current Nanoscience <i>In vivo</i> Anticancer Potential of Hydroxamic Acid Derivatives
Current Topics in Medicinal Chemistry Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents
Current Medicinal Chemistry Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging